

Special Issue

Vaccines and Vaccine Adjuvants for Infectious Diseases and Autoimmune Diseases

Message from the Guest Editor

Vaccines are essential in eradicating or controlling many infectious diseases. In this context, several possible mechanisms (epitope spreading, bystander activation, molecular mimicry, etc.) are postulated. In addition, microbial components are indispensable in several animal models of autoimmune diseases. Recent concerns in this area include the autoimmune manifestations associated with COVID-19 vaccines, although incidences of autoimmune diseases after other vaccinations were reported as well. At the same time, people living with autoimmune disease(s) need to take care of themselves to protect against various infections. Therefore, on this topic, we invite original and review articles covering the following three aspects: 1. Central theme: development of vaccines for infectious diseases or autoimmune diseases; 2. Exploration: how vaccines for infectious diseases might cause autoimmune diseases; 3. Accessories: vaccine adjuvants (natural and synthetic polymers, microbial and nonmicrobial components, their mode of action, and beneficial and adverse effects).

Guest Editor

Prof. Dr. Kutty Selva Nandakumar

Department of Environmental and Biosciences, School of Business, Innovation and Sustainability (FIH), Halmstad University, Halmstad, Sweden

Deadline for manuscript submissions

closed (31 May 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/143704

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).